Alnylam Pharmace. buy JPMorgan Chase & Co.
Start price
16.07.25
/
50%
€277.50
Target price
16.07.26
€299.70
Performance (%)
32.14%
Price
09:30
€366.70
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace. has seen massive gains of 32.14%. This prediction currently runs until 16.07.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -5.644% | -5.644% |
| iShares Core DAX® | 1.917% | 1.088% |
| iShares Nasdaq 100 | 0.911% | 1.674% |
| iShares Nikkei 225® | 0.833% | -1.712% |
| iShares S&P 500 | 0.242% | 1.258% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $338.00 to $348.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat